Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Year Of Paxlovid - Where Is The Licensed Generic?

Hetero Gets First WHO PQ; Chinese, Korean Companies In The Wings

Executive Summary

It’s been a year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir. Scrip looks at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023 as Hetero's version becomes the first with WHO Prequalification while two Chinese and a Korean company wait in the wings.

You may also be interested in...

Nilotinib Patent Expiry Leaves Door Open For India Generics, Other Markets Could Face Longer Wait

The expiry of Novartis’ nilotinib compound patent in July leaves the door open for Tasigna generics in India. Medicines Patent Pool sub-licensees like Hetero and Dr. Reddy’s are also free to launch their generics as the agreement doesn’t include the Indian market. However, MPP sub-licensee plans for other markets involve a tougher regulatory path

Will ViiV’s Regulatory Stance Delay Access To Cabotegravir Despite MPP Deal?

Scrip looks at the contours of MPP’s recent sub-licensing deal for ViiV Healthcare’s cabotegravir with Cipla, Aurobindo and Mylan, along with pricing dynamics and precedents to evaluate a few barriers to access

Jan Deadline For API QR Codes In India Arrives; Are Local, Chinese Firms Prepared?

Beginning January, packaging on active pharmaceutical ingredients (APIs) made in or imported into India is to bear a QR code, but the Indian industry is unprepared and feels the move isn’t beneficial. With about 70% of the country’s API imports coming from China, questions remain on its implementation too

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts